Metastatic Pancreatic Cancer With George P. Kim, MD, and Eileen M. O'Reilly, MD: Case 1 - Episode 4
Has the frontline standard of care shifted toward the nab-paclitaxel/gemcitabine regimen?
I think the standard of care has shifted to the gemcitabine/nab-paclitaxel frontline approach. And, getting back to the NCCN guidelines, that does make sense. What’s happening is that we have two approved drugs and the gemcitabine/nab-paclitaxel, if given upfront, can logically be changed to an irinotecan-based treatment, the Onivyde nanoparticle liposomal irinotecan. It makes sense to use that sequence because you avoid some of the neuropathy that can carry over. The NAPOLI regimen or the nal-IRI regimen has no neuropathy associated with it. It also has a very low rate of thrombocytopenia, which is another reason that patients come off of frontline gemcitabine/abraxane. So it makes sense from an efficacy standpoint but also in the types of toxicities, the reasons the patients come off of first-line treatment to go from one regimen to the next.
Metastatic Pancreatic Cancer: Case 1
Larry D, a 62-year-old, presented to his primary care physician with persistent pain in his epigastric region, which persists throughout the night. Within the past 2 years, he has developed diabetes and experienced considerable weight loss with signs of depression.
Larry went on to receive the combination of nab-paclitaxel and gemcitabine as frontline therapy for 5 months: